Skip to main content

New Gene Editing Trial Results Bump the ARKG ETF

Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) surged Monday after the firm and another company known as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) over the weekend announced positive results from an ongoing Phase I clinical trial for an in vivo genome editing therapy known as NTLA-2001....
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.